Guillermo Garcia-Manero, MD

Guillermo Garcia-Manero, MD, is director of the Fellowship Program, the Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research, deputy chair of Translational Research, a professor, and chief of the Section of Myelodysplastic Syndromes in the Department of Leukemia, as well as leader of the MDS/AML Moon Shot Program at The University of Texas MD Anderson Cancer Center in Houston.

Articles

How Data Are Defining the Role of Luspatercept in ESA-Naive, Lower-Risk MDS

July 10th 2025

Guillermo Garcia-Manero, MD, highlights clinical trial findings and real-world data for luspatercept in ESA-naive, lower-risk MDS.

OS Data From COMMANDS for Luspatercept in ESA-Naive, Lower-Risk MDS

June 26th 2025

Guillermo Garcia-Manero, MD, discusses OS data from the COMMANDS trial for luspatercept in ESA-naive, lower-risk MDS.

Recent Shifts in the Management of Lower-Risk MDS

June 19th 2025

Guillermo Garcia-Manero, MD, highlights recent shifts in the lower-risk myelodysplastic syndrome treatment paradigm.

The Potential of Oral HMAs in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the potential for the use of oral HMAs in MDS.

Where Imetelstat Fits Into the Paradigm for Transfusion-Dependent Anemia in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the implications of the FDA approval of imetelstat for transfusion-dependent anemia in MDS.

Other Potential Roles for Luspatercept in MDS And Beyond

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss other potential roles for luspatercept in MDS and beyond.

Long-Term Transfusion Independence Data for Luspatercept vs ESAs in Lower-Risk MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss long-term transfusion independence data for luspatercept in MDS.

Optimal Goals for Anemia and Transfusion Independence in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on treatment goals for anemia and transfusion independence in MDS.

Clinical Implications of FDA Approval of Luspatercept for Anemia in ESA-Naive Lower-Risk MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on the FDA approval of luspatercept in ESA-naive lower-risk MDS.

The Importance of Treating Anemia in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the importance of treating anemia in myelodysplastic syndrome.

Dissecting the Current Treatment Landscape in MDS

December 18th 2024

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.

Garcia-Manero on MDS Treatment Updates With Luspatercept and Beyond

August 19th 2024

Dr Garcia-Manero discusses findings from research in myelodysplastic syndromes that were presented at the 2024 EHA Congress.

Final Thoughts on EHA 2024 Data for Lower-Risk MDS

August 16th 2024

Key opinion leaders summarize their main insights and key takeaways from the EHA 2024 conference regarding advances in lower-risk myelodysplastic syndrome treatment.

EHA 2024 Future Directions in Lower-Risk MDS Treatment: Emerging Data, Approvals, and Guideline Updates

August 16th 2024

The expert panel explores the future landscape of lower-risk myelodysplastic syndrome treatment, considering recent approvals and emerging clinical data.

Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024

August 10th 2024

Key opinion leaders (KOLs) examine real-world evidence and draw on their clinical experiences to inform their practice, discussing real-world dose escalations and key insights gained from practical application.

Perspectives of IMerge Study

August 10th 2024

Medical professionals deliberate on patient selection criteria for second-line imetelstat treatment in lower-risk myelodysplastic syndromes, incorporating findings from the IMerge study into their considerations.

Sequencing Second-Line Treatments for LR-MDS

August 2nd 2024

Medical experts discuss sequencing strategies for second-line and later treatments in lower-risk myelodysplastic syndromes, examining how recent data, including insights from the MEDALIST trial, influence treatment selection and sequencing decisions.

1L treatment of lower-risk MDS beyond luspatercept

August 2nd 2024

Medical experts explore alternative treatment options for lower-risk myelodysplastic syndrome (LR-MDS) patients who are not suitable candidates for first-line luspatercept therapy.

Safety Profile of Available Frontline Treatments LR-MDS

July 29th 2024

Key opinion leaders evaluate the safety profiles of available frontline treatments for patients with lower-risk myelodysplastic syndromes, including observed adverse reactions.

Dr.'s Cluzeau and Komrokji on Utilization Patterns of luspatercept in LR-MDS EHA 2024 Data

July 29th 2024

Medical professionals examine the utilization patterns of luspatercept in lower-risk myelodysplastic syndromes (LR-MDS) and their impact on patient treatment strategies.